PanOmiQ completes Whole Genome Sequencing analysis with a
clinical report in 7 hours.
CALGARY,
AB, April 25, 2024 /CNW/ - BioAro, a
pioneer in genomic research and technology, is set to officially
launch PanOmiQ, a revolutionary software that will redefine
the landscape of genomic analysis globally by providing real-time
insights into the complexities of the human genome. With
unparalleled speed, precision, and versatility, it promises to
transform healthcare worldwide. The Global launch of PanOmiQ
software will take place during the Precision Medicine Expo on
May 9th, 2024, at
Dubai World Trade
Center, UAE.
BioAro's, Founder and CEO, Dr. Anmol
S. Kapoor, shared "Our team at BioAro are committed to
pushing the boundaries of genomic research and technology through
real-time genomic testing and analysis to provide enhanced quality
of life and Healthspan. With the launch of PanOmiQ, we are ushering
in a new era of precision medicine, where every patient receives
tailored treatments based on their unique genetic makeup."
Joining him at this prestigious launch is Dr. George Patrinos, Professor and Head of the
Laboratory of Pharmacogenomics and Individualized Therapy at the
Department of Pharmacy, University of Patras (Greece). Dr. Patrinos acknowledges PanOmiQ as
a groundbreaking solution that seamlessly integrates results from
multiple omics disciplines, providing a comprehensive report for
personalized health decisions in real-time. He believes that this
innovative software offers a holistic solution for precision health
and longevity.
As the culmination of years of research and development, PanOmiQ
stands as the world's fastest genomic analysis software to date.
With its unified approach integrating primary, secondary, and
tertiary analysis of genomic and metagenomic data, it enables
healthcare specialists to decode DNA sequences in real-time,
empowering them to make informed decisions.
"Turnaround time in genomic analysis is critical, and this is
where PanOmiQ comes in with its unmatched speed and accuracy. The
proprietary AI- platform also provides clinical annotations and
helps better understand disease risk." said Dr. Raja B. Singh, Chief Scientific Officer at
BioAro. While it once took 13 years to screen the human genome and
now it typically takes around 4 weeks, PanOmiQ pushes the
boundaries even further, completing the process in just 7
hours. This remarkable efficiency not only streamlines
processes but also reduces costs associated with ineffective
treatments and prolonged recovery periods. By democratizing access
to genomic information, PanOmiQ aims to make precision medicine
universally accessible and affordable, transcending geographical
and socioeconomic barriers.
Dr. Minal Borkar Tripathi,
Director of Genomics at BioAro, said, "With the power of artificial
intelligence, PanOmiQ helps identify rare diseases, health
predispositions, and pharmacogenomic insights with unmatched speed
and precision. Its ability to provide Pharmacogenomic analysis is a
major advancement in tailoring treatment for optimal patient
care."
PanOmiQ's capabilities extend to microbial community analysis
(metagenomics), medication tolerance assessment (pharmacogenomics),
and soon, MultiOmics for proteins, metabolites, and the
transcriptome. This approach enables the identification of
biomarkers influenced by lifestyle, medications, and environmental
factors, facilitating tailored healthcare interventions for
multifactorial disorders like irritable bowel syndrome (IBS),
rooted in dysbiosis, mental health issues, and lifestyle
factors.
PanOmiQ excels not only in analysis but also in its
compatibility with various genetic file formats like FastQ and VCF,
streamlining workflows and integrating seamlessly into existing
processes. While AI ensures efficiency, PanOmiQ utilizes 20+ sets
of databases to ensure accuracy and highly detailed results.
The future of genomic science is on the brink of transformation
with the integration of Quantum technology. BioAro's PanOmiQ leads
this revolution, harnessing Quantum technology to redefine
possibilities in this field. With real-time, precise genomic
sequencing and interpretation on quantum-based computers, the
future of genomic research is rapidly advancing, and BioAro is
actively invested in driving innovation and pushing the boundaries
of what's possible in genomic science.
Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro
will introduce PanOmiQ's groundbreaking capabilities. Register at
www.PanOmiq.com and secure your reservation and experience the
future of real-time genomics analysis firsthand.
About BioAro Inc.
BioAro is a Precision Health, HealthSpan, and Longevity Biotech
Company committed to pioneering innovative solutions for optimal
well-being. With a focus on research, development, and
implementation, BioAro aims to lead the way in advancing precision
health strategies that enhance healthspan and longevity.
For more information, visit: www.bioaro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bioaro-announces-a-medical-and-computing-breakthrough-by-launching-the-worlds-fastest-real-time-genomic-software-panomiq-302127201.html
SOURCE BioAro Inc.